Evaluating citrate anticoagulation in kidney treatment for liver failure patients
Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their Complications
This study is testing if using citrate anticoagulation during kidney treatment helps critically ill patients with liver failure and kidney injury recover better and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Antwerp Academic / other |
| Locations | 1 site (Edegem, Antwerp) |
| Trial ID | NCT06908746 on ClinicalTrials.gov |
What this trial studies
This observational study examines the efficacy and safety of citrate anticoagulation during continuous renal replacement therapy (CRRT) in critically ill patients suffering from liver failure and acute kidney injury (AKI). It aims to determine how the underlying cause of liver failure affects the incidence of citrate-related complications and to compare outcomes such as renal recovery and patient survival. The study will analyze data retrospectively to assess the impact of citrate anticoagulation on filter lifespan and overall patient outcomes in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include critically ill adults aged 18 and older with documented liver failure and AKI requiring CRRT.
Not a fit: Patients without liver failure or those not requiring CRRT may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment protocols for patients with liver failure undergoing CRRT, potentially enhancing their recovery and survival rates.
How similar studies have performed: While the use of citrate anticoagulation in CRRT has been explored, this specific focus on liver failure patients is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Critically ill patients diagnosed with AKI requiring CRRT. Caution Protocol V1.0 24-07-2024 * Documented liver failure or significant liver dysfunction (e.g., elevated liver enzymes, bilirubin levels, or clinical diagnosis of liver failure) and clincal diagnosis of shock (NE of 0.25 μg/kg/min and or association of second vasopressor). * Age ≥ 18 years. Exclusion Criteria: * NA
Where this trial is running
Edegem, Antwerp
- Antwerp University Hospital — Edegem, Antwerp, Belgium (Recruiting)
Study contacts
- Principal investigator: Rita Jacobs, Dr. — Antwerp Univesity Hospital
- Study coordinator: Rita Jacobs, Dr.
- Email: rita.jacobs2@uza.be
- Phone: +32 3 821 36 35
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.